Bispecific Antibodies in R/R MM
Relapsed/Refractory Multiple Myeloma: Role and Safety of Bispecific Antibodies

Released: October 24, 2024

Expiration: October 23, 2025

Caitlin Costello
Caitlin Costello, MD

Activity

Progress
1
Course Completed

In this episode, Caitlin Costello, MD, discusses important topics related to relapsed/refractory (R/R) multiple myeloma (MM), including:

  • 3 bispecific antibodies approved for the treatment of R/R MM that target BCMA or GPRC5D
  • The role of bispecific antibodies in R/R MM
  • Safety considerations for patients while receiving a bispecific antibody
  • Emerging data and clinical trials with  bispecific antibodies
  • Key clinical pearls for optimal use of bispecific antibodies